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Gammaglobulins in critical care
Gamaglobulinas em Terapia Intensiva
Fabio Carmona1
ABSTRACT
The use of intravenous immunoglobulin (IVIG) is relatively infrequent in patients admitted to intensive
care units (ICUs). However, “off-label” IVIG prescriptions for different conditions are highly prevalent. The
aim of this paper is to review the existing evidence for the use of IVIG in patients admitted to ICUs,
emphasizing non-infectious diseases and complications: hypogammaglobulinemia of the critically ill,
hemophagocytic lymphohistiocytosis (HLH), Guillain-Barré syndrome (GBS), Kawasaki disease (KD),
chylothorax, acute myocarditis, toxic shock syndrome (TSS), Stevens-Johnson syndrome (SJS)/toxic epi-
dermal necrolysis (TEN), and sepsis.
In conclusion, in critically ill patients, IVIG use is of benefit in KD, GBS, and TSS. It may benefit patients
with fulminant acute myocarditis. The benefit is not proven in patients with HLH, chylothorax, and SJS/
TEN.
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Introduction
Intravenous immunoglobulin (IVIG) is derived
from great amounts of human serum, prepared for in-
travenous injection. Initially developed during the
1940’s for intramuscular use, its use became more dis-
seminated only after the availability of the intravenous
preparation, by the end of the 20th century. Since it
shows a variety of activities, IVIG has been investi-
gated in the prophylaxis and treatment of a number of
infectious and non-infectious diseases. Currently, the
Food and Drug Administration (FDA) approves only
six indications for the use of IVIG: primary deficiency
of gammaglobulins, idiopathic thrombocytopenic pur-
pura, Kawasaki disease (KD), HIV infection in chil-
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dren, chronic β-cell lymphocytic leukemia, and bone
marrow transplant.1
However, many other “off-label” uses have been
investigated and even recommended, including severe
sepsis, septic shock, toxic shock syndrome (TSS), non-
immune thrombocytopenia, prophylaxis of perioperative
infections1, Guillain-Barré syndrome (GBS), hemo-
phagocytic lymphohistiocytosis (HLH), chylothorax,
acute myocarditis, and Stevens-Johnson syndrome
(SJS). A recently published review of IVIG use in 12
academic centers in the United States (US) showed
that IVIG is used for more than 50 different condi-
tions. Fifty-two percent of them were considered “off-
label”.2 In a Canadian study, IVIG use in patients ad-
mitted to intensive care units (ICUs) was relatively
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infrequent: from 145 prescriptions, 19% were consid-
ered adequate, while 74% were considered “off-la-
bel,” and 7% were considered inadequate.1 In that
study, the main indications for IVIG use were GBS,
toxic epidermal necrolysis (TEN), and necrotizing
fasciitis.
Given the controversy regarding the use of IVIG,
especially in critically ill patients, the objective of this
article is to review the usefulness of IVIG in critically
ill patients, with emphasis on non-infectious diseases
and complications.
Hypogammaglobulinemia of critically ill pa-
tients
During a critical illness, adult and pediatric pa-
tients can exhibit low plasma concentrations of immu-
noglobulins. In children admitted to the ICU, the inci-
dence of hypogammaglobulinemia can reach 70%.3,4
The meaning of this phenomenon is not clear. It is
possible that it is a normal part of acute response to
stress, just like alterations in cortisol, insulin, and en-
dogenous catecholamines, but it is also possible that
the phenomenon is associated with a transient immu-
nodeficiency with impairment of the host defenses
against pathogenic microorganisms.3
To date, there is no evidence to support routine
immunoglobulin supplementation in critically ill patients.
However, patients with severe infections and documen-
ted hypogammaglobulinemia may experience benefit.3
Hemophagocytic Lymphohistiocytosis (HLH)
HLH is a severe disease that can occur as a
familial type, or as a secondary reaction to infectious,
rheumatologic, or malignant diseases.5 When HLH is
secondary to rheumatologic diseases, it can also be
named macrophage activation syndrome (MAS). The
initial diagnosis is clinical, based on the presence of
fever, splenomegaly, cytopenia, elevated ferritin, el-
evated triglycerides, and lowered fibrinogen. There can
also be impairment of natural killer cell function and
elevated soluble CD25.5 The diagnosis is confirmed
by the presence of hemophagocytosis in bone marrow
aspirates.6
The majority of patients require intensive care
during the episodes. However, the best therapeutic
regimen is not established. It can include corticoster-
oids alone, IVIG alone, or different combinations of
corticosteroids, IVIG, etoposide, and cyclosporine. The
efficacy of IVIG in this setting is not still well estab-
lished.5
In a study of 38 children with HLH/MAS in
Canada, the use of corticosteroids and/or IVIG as first
line treatments was considered sufficient.5 Parekh et
al published a series of 3 children with HLH where all
received IVIG, and they reported disease remission
after 3–7 weeks.7 Lin et al studied 8 children with MAS
and concluded that IVIG use (1 g/kg/day) was effi-
cient in controlling the disease in 33% of cases, as
well as cyclosporine and corticosteroids in the other
cases.8
Since studies addressing IVIG use in HLH/MAS
are scarce and controversial, the efficacy of IVIG in
these conditions is still not established.9-13
Guillain-Barré Syndrome (GBS)
GBS is currently the most common cause of
flacid acute paralysis after the reduction of the inci-
dence of poliomyelitis. The syndrome usually follows
an acute bacterial or viral infection. The most com-
mon agent is Campylobacter jejuni, but the disease
can also follow vaccination against measles, tetanus,
poliomyelitis, Meningococcus, rubella, influenza and
hepatitis B. It is characterized by ascending polyneu-
ropathy, frequently involving motor nerves and, less of-
ten, sensorial and autonomic nerves. It starts with pro-
gressively ascending symmetric muscle weakness that
can involve the respiratory muscles and lead to respi-
ratory failure with need for mechanical ventilation.14
The use of IVIG patients with GBS admitted to
ICUs is discussed elsewhere in this issue. In sum-
mary, IVIG is considered as effective as plasma ex-
change in hastening symptoms of GBS if started within
two weeks from disease onset.15
Kawasaki Disease (KD)
KD is an acute, self-limited vasculitis occurring
mainly in children of all ages.16 The disease can lead
to coronary artery aneurisms, being the main cause of
acquired heart disease in children from developed
countries. The fist-line treatment includes aspirin and
IVIG17, but some patients may not respond. Besides,
the first-line treatment may be delayed due to incor-
rect diagnosis of septic shock or TSS.16  In a large
cohort of 423 children with KD, those who needed
admission to an ICU (3.3%) have had longer delays in
administration of IVIG, and higher proportion of IVIG
resistance. These patients needed a second dose of
IVIG or other immunosuppressant therapy.16
In 1984, Japanese researchers published a ran-
domized clinical trial on two different treatments for
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KD: aspirin (n=45) versus IVIG (n=40). Patients
treated with IVIG had lower incidence of coronary
aneurisms after 29 days (15 vs. 42%).18 Two years
later, Newburger et al published another study on 79
children with KD, and concluded that a high-dose of
IVIG (400 mg/kg/day for 4 days) was safe and effec-
tive in decreasing the incidence of coronary abnor-
malities if administered early in disease course.19
Recently, a retrospective study on 359 children
with KD who did not respond to the initial IVIG dose
showed that rescue therapy with IVIG plus pred-
nisolone was more effective than IVIG or prednisone
alone in controlling the disease.17 This year, Park et al
published a study on 309 children with KD, of whom
only 30 (7.9%) did not respond to an initial IVIG dose.
Patients who did not respond to IVIG had longer
hospital stay and higher incidence of coronary le-
sions. Two risk factors for first-dose IVIG resistance
were identified: ALT ≥ 84 IU/L and total bilirubin ≥
0.9 mg/dL.20
Therefore, IVIG is effective in decreasing the
incidence of coronary disease after KD, and can also
be used as a rescue therapy after first-dose failure,
associated or not to corticosteroids.
Chylothorax
Chylothorax is a relatively rare complication,
occurring more commonly after pediatric heart sur-
gery. Its estimated incidence is between 1 and 5%.21
This complication can lead to higher morbidity and
longer ICU and hospital stay. The lymphocyte deple-
tion and gammaglobulin loss in the lymph can lead to
secondary immunodeficiency. Since IVIG use is well
established in the treatment of primary immunodefi-
ciencies, it could be useful in this setting. However,
the guidelines for chylothorax management do not
emphasize the need of immunoglobulin replacement.22
McBride et al reported 2 cases of chylothorax
following heart surgery in children that resulted in
hypogammaglobulinemia. In this study, serum level of
gammaglobulins increased after IVIG infusion.22 In
another study, on a cohort of 37 children with chylot-
horax after heart surgery, those with greater lymph
losses exhibited lower serum levels of gammaglobulins.
However, IVIG use did not lowered the incidence of
infections.21
Therefore, IVIG use in patients with chylotho-
rax following heart surgery can increase serum levels
of gammaglobulins, especially when they are low, but
the benefit is not established yet.
Acute Myocarditis
Acute myocarditis is defined as an acute in-
flammation within the myocardium caused by a non-
specific viral infection.23 Its severity can vary from
subclinical dysfunction up to heart failure and cardio-
genic shock.
Treatment includes mechanical ventilator sup-
port, inotropes like milrinone, dobutamine and levosi-
mendan, and, in severe cases, mechanical circulatory
support. The most used modalities for circulatory sup-
port are extracorporeal membrane oxygenation
(ECMO) and ventricular assistance devices (VAD).
In cases where the myocardium do not recover, heart
transplantation might be necessary.24
In the pediatric population, some studies have
reported success after immunomodulatory treatments
with IVIG and corticosteroids, alone or in combina-
tion.23 In animal models of myocarditis, IVIG use
showed encouraging results, but in humans the results
were disappointing.24 In France, in a series of 11 cases
of children with acute myocarditis, all received corti-
costeroids, and seven received IVIG (2 g/kg in 24
hours). In this series, only one death (9%) was re-
corded.23 In a multicenter trial with 216 children with
acute myocarditis, 49.1% received IVIG as part of
their treatment. However, IVIG did not alter mortal-
ity, not even in the subgroup of more severe patients.25
Therefore, routine IVIG use in acute myocar-
ditis is not recommended, although some authors still
advocate it in patients with fulminant myocarditis.24
Toxic Shock Syndrome (TSS)
TSS is an invasive infection caused by group-A
β-hemolytic Streptococci.26 Mortality is extremely
high (up to 80%) despite antibiotic therapy.26  It is char-
acterized by hypotension and multiple organ failure
early in disease course. There is evidence that lack of
humoral immunity protecting against bacterial super-
antigens might be involved in the genesis of the dis-
ease. This fact led many authors to propose IVIG use
for treatment of TSS, because of the possibility of su-
perantigens neutralization and enhanced opsonization.26
In 1999, Kaul et al published a series of 21 cases
of TSS treated with IVIG (2 g/kg/day) compared to
historic controls. Patients that received IVIG have had
a higher survival rate (67 vs. 34%, p=0.02).27 Later, a
randomized multicenter trial on 21 adult patients with
TSS (10 received IVIG) showed a 3.6-fold reduction
in mortality and a significant reduction on the incidence
13
Carmona F. Gammaglobulins in Critical Care
Medicina (Ribeirão Preto) 2014;47(1):10-15
http://revista.fmrp.usp.br/
of multiple organ failure in patients receiving IVIG.26
In a larger randomized multicenter trial of 192 chil-
dren with TSS, 84 (44%) received IVIG as part of
their treatment regimen. For these patients, total hos-
pital cost was significantly higher, and outcomes were
the same.28
Therefore, IVIG use is associated with de-
creased mortality in adults with TSS. In children, the
benefit is still unproven.
Stevens-Johnson Syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN)
SJS and TEN are severe cutaneous reactions,
usually to drugs, associated with disseminated epider-
mal destruction.29 Both diseases are closely related:
SJS is a self-limited form characterized by erosions in
mucous membranes and blisters in less than 10% of
body surface area, while TEN resembles severe burns
due to the confluence of erosions and blisters in more
than 30% of body surface area. Therefore, there are
cases with superposition of the two definitions, de-
pending on the extension of skin lesions.29 It is a rare
condition (1.5-–2 cases per million inhabitants per
year), but with high mortality (20–25%).30
No treatment has been proven as beneficial for
these diseases to date. Many authors advocate the use
of corticosteroids and immunosuppressant drugs. Labo-
ratory data suggest that IVIG might be useful because
it can prevent Fas-ligand protein from binding to Fas
receptor, which is augmented in the disease.31 How-
ever, to date, no prospective study confirmed the IVIG
utility in patients with SJS/TEN.32 Most benefits have
been shown in retrospective studies.30
In a study of 12 patients with TEN in Europe
and United States, treatment with IVIG (1 g/kg/day
for 3 days) resulted in faster resolution of epidermal
detachment and 88% survival.33 In Italy, 10 patients
with TEN received smaller doses of IVIG (400 mg/
kg/day for 5 days) and had a lower-than-predicted
mortality (10 vs. 35%).34 Metry et al showed that the
same benefit extends to pediatric patients.35 In that
study, involving 28 children with SJS/TEN, appearance
of new blisters was halted 24–48 hours after IVIG
infusion. In France, in a study of 34 adults with SJS/
TEN, all received IVIG (2 g/kg), and the observed
mortality (32%) was superior to the mortality predicted
by severity scores (24%), thus not supporting IVIG
use for the treatment of SJS/TEN in adults.29 Also in
children, Morici et al compared the outcomes of pa-
tients with SJS who received (n=7) or not (n=5) IVIG
(1.5-–2 g/kg), and observed that those receiving IVIG
had shorter fever duration and shorter hospital stay.36
In the United States, another study compared
patients with TEN who received (n=24) or not (n=21)
IVIG, and showed that mortality was higher in patients
receiving IVIG (41.5 vs. 28.6%, p=NS). In this study,
patients receiving IVIG also had longer hospital stay.32
In 2006, another retrospective study showed that IVIG
use (2.8 g/kg/day) in 23 patients with TEN resulted in
lower mortality (26%) compared to 8 patients who did
not receive IVIG (75%).30
The larger retrospective study on IVIG use in
SJS/TEN was published in 2008 (EuroSCAR) and in-
cluded 379 patients. IVIG administration (1.9 g/kg)
did not result in any benefit compared to support
therapy.37 The study used smaller-than-recommended
doses of IVIG, and the group receiving IVIG had larger
body surface involvement. The study by Yang et al, in
2009, on 65 patients (20 receiving IVIG) showed lower-
than-predicted mortality on patients receiving IVIG,
although differences were not statistically significant.38
More recently, a study compared clinical and
treatment characteristics of children with SJS/TEN
admitted to two different hospitals, one American and
one Canadian, and showed that therapeutic regimens
varied broadly between the two hospitals, but the out-
comes were similar. IVIG use was higher in the Ameri-
can hospital (65 vs. 23%).39
Although most studies favor IVIG use in pa-
tients with SJS/TEN, some do not support the benefit.
Many of these studies used IVIG doses below the
recommended. Moreover, IVIG was administered too
late in the disease course. Therefore, there is a need
for controlled studies with adequate doses and timing
of IVIG, so the benefits can be proven. Nevertheless,
the benefits may not only involve reductions in mortal-
ity but also on halting disease progression.30
Sepsis
Controling the hyper-inflammation is one of the
strategies used in the treatment of severe sepsis and
septic shock. For this aim, it is very unlikely that the
patient arrives in the emergency room early enough to
control the hyper-inflammation with only one drug.
Thus it seems that a combination of drugs may be more
efficient.40 Data extrapolated from pre-clinical studies
suggest that IVIG administration may ameliorate
bacterial elimination, inhibit nuclear factor kappa-B
(NF-κB) activation, block inflammatory mediators, at-
tenuate lymphocyte apoptosis, and have anti-inflam-
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RESUMO
O uso de imunoglobulina intravenosa (IVIG) é relativamente infrequente em pacientes internados em
unidades de terapia intensiva (UTIs). Entretanto, prescrições “off-label” de IVIG para diferentes
patologias são altamente prevalentes. O objetivo deste artigo é revisar as evidências existentes para o
uso de IVIG em pacientes internados em UTIs, enfatizando as doenças e complicações não infeccio-
sas: hipogamaglobulinemia do paciente crítico, linfo-histiocitose hemofagocítica (HLH), síndrome de
Guillain-Barré (GBS), doença de Kawasaki (KD), quilotórax, miocardite aguda, síndrome do choque
tóxico (TSS), síndrome de Stevens-Johnson (SJS)/necrólise epidérmica tóxica (TEN), e sepse.
Em conclusão, em pacientes criticamente enfermos, o uso de IVIG é benéfico em KD, GBS e TSS. IVIG
pode ser benéfica em pacientes com miocardite aguda fulminante. O benefício não foi comprovado em
pacientes com HLH, quilotórax e SJS/TEN.
Palavras-chave: Imunoglobulina. Gamaglobulina. Terapia Intensiva. Cuidados Intensivos.
matory effects. However, it is still necessary to better
characterize changes in blood levels of immunoglobu-
lins that accompany sepsis, as well as the underlying
mechanisms and the likelihood of benefits following
IVIG administration.
Currently, the 2012 Guidelines of the Surviving
Sepsis Campaign suggests “not using intravenous im-
munoglobulins in adult patients with severe sepsis or
septic shock (grade 2B)”.41 There are no recommen-
dations for children.
Conclusion
In conclusion, in critically ill patients, IVIG use
is of benefit in Kawasaki disease, Guillain-Barré syn-
drome and toxic shock syndrome. It may offer benefit
to patients with fulminant acute myocarditis. The ben-
efit is not proven in patients with hemophagocytic
lymphohistiocytosis, chylothorax, and Stevens-Johnson
syndrome/toxic epidermal necrolysis.
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